Table 2.
The association between CXCL4L1 expression and clinicopathological characteristics of prostate cancer
| Clinicopathological characteristics | CXCL4L1 expression | P | |
|---|---|---|---|
| Low (n=106) | High (n=107) | ||
| Age (year), median (IQR) | 67.0 (55.5–73.0) | 63.0 (58.0–70.5) | 0.332a |
| BMI (kg m−2), median (IQR) | 24.8 (23.3–26.6) | 24.5 (22.5–26.1) | 0.415a |
| PSA (ng ml−1), median (IQR) | 13.2 (8.9–18.3) | 11.3 (7.8–19.5) | 0.159a |
| PSAD (ng ml−1 cm−3), median (IQR) | 0.22 (0.15–0.31) | 0.19 (0.13–0.29) | 0.143a |
| Surgical margin, n (%) | |||
| Negative | 73 (68.9) | 88 (82.2) | 0.023b |
| Positive | 33 (31.1) | 19 (17.8) | |
| Tumor multifocality, n (%) | |||
| Unifocal | 55 (51.9) | 79 (73.8) | 0.001b |
| Multifocal | 51 (48.1) | 28 (26.2) | |
| Pathological Gleason score, n (%) | |||
| ≤6 | 10 (9.4) | 29 (27.1) | <0.001b |
| 7 (3+4) | 15 (14.2) | 17 (15.9) | |
| 7 (4+3) | 18 (17.0) | 47 (43.9) | |
| ≥8 | 63 (59.4) | 14 (13.1) | |
| Pathological T stage, n (%) | |||
| pT2 | 60 (56.6) | 85 (79.4) | 0.002b |
| pT3 | 30 (28.3) | 15 (14.1) | |
| pT4 | 16 (15.1) | 7 (6.5) | |
| CAPRA score, n (%) | |||
| ≤2 | 9 (8.5) | 20 (18.7) | 0.013b |
| 3 | 10 (9.4) | 21 (19.6) | |
| 4 | 17 (16.1) | 19 (17.8) | |
| 5 | 19 (17.9) | 12 (11.2) | |
| ≥6 | 51 (48.1) | 35 (32.7) | |
P values were obtained from the aMann–Whitney U test or bChi-square test. BMI: body mass index; PSA: prostate-specific antigen; PSAD: prostate-specific antigen density; T: tumor; pT: pathological tumor; CAPRA: Cancer of the Prostate Risk Assessment; IQR: interquantile range; CXCL4L1: plate factor-4 variant